Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Titel:
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Auteur:
Erba, Harry P. Becker, Pamela S. Shami, Paul J. Grunwald, Michael R. Flesher, Donna L. Zhu, Min Rasmussen, Erik Henary, Haby A. Anderson, Abraham A. Wang, Eunice S.